Payment overview · 2025
General Payments
$625.83
26 reported records · 10 companies
Healthcare provider profile · identity verified
Wayne Dwight Austin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WINDER, GA · NPI 1306959754
Verified facts
What the public records show
CMS Open Payments records show Wayne Dwight Austin, M.D. received $625.83 in general payments during 2025 across 26 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.38 | 19.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.94 | 16.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $102.61 | 16.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $98.56 | 15.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.97 | 9.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.63 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.03 | 5.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.47 | 4.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.74 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.50 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $625.83 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.94 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $98.56 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.55 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.25 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.97 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.47 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 785 | 250 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 783 | 244 |
| Amlodipine Besylate | Amlodipine Besylate | 715 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 139 |
| Losartan Potassium | Losartan Potassium | 388 | 117 |
| Omeprazole | Omeprazole | 244 | 75 |
| Lisinopril | Lisinopril | 235 | 70 |
| Metformin Hcl Er | Metformin Hcl | 224 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 43 |
| Metformin Hcl | Metformin Hcl | 132 | 42 |
| Alprazolam | Alprazolam | 130 | 27 |
| Gabapentin | Gabapentin | 129 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 37 |
| Montelukast Sodium | Montelukast Sodium | 118 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 38 |
| Potassium Chloride | Potassium Chloride | 116 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 36 |
| Mounjaro | Tirzepatide | 112 | 24 |
| Sertraline Hcl | Sertraline Hcl | 109 | 39 |
| Eliquis | Apixaban | 108 | 26 |
| Famotidine | Famotidine | 107 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 45 |
| Trazodone Hcl | Trazodone Hcl | 107 | 37 |
| Carvedilol | Carvedilol | 106 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 37 |
| Clonazepam | Clonazepam | 100 | 21 |
| Farxiga | Dapagliflozin Propanediol | 94 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 29 |
| Glipizide Er | Glipizide | 92 | 30 |
| Trulicity | Dulaglutide | 91 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 29 |
| Simvastatin | Simvastatin | 88 | 24 |
| Alendronate Sodium | Alendronate Sodium | 84 | 24 |
| Jardiance | Empagliflozin | 82 | 25 |
| Tramadol Hcl | Tramadol Hcl | 82 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 22 |
| Furosemide | Furosemide | 79 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 28 |
| Allopurinol | Allopurinol | 70 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 19 |
| Meloxicam | Meloxicam | 57 | 20 |
| Ozempic | Semaglutide | 54 | 12 |
| Azithromycin | Azithromycin | 53 | 47 |
| Lovastatin | Lovastatin | 52 | 15 |
| Celecoxib | Celecoxib | 51 | 15 |
| Atenolol | Atenolol | 50 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 14 |
| Ramipril | Ramipril | 49 | 12 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 13 |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Finasteride | Finasteride | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $625.83 · 26 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, JARDIANCE, Korlym, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error